5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine
C25H25F3N6O — CID 11237028
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine
5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine (PubChem CID 11237028) has the molecular formula C25H25F3N6O and a molecular weight of 482.51 g/mol. Its IUPAC name is 5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine.
Molecular Properties
| Compound Name | 5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine |
|---|---|
| PubChem CID | 11237028 |
| Molecular Formula | C25H25F3N6O |
| Molecular Weight | 482.51 g/mol |
| Exact Mass | 482.20 |
| IUPAC Name | 5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-f][1,2,4]triazin-2-amine |
| SMILES | Cc1nc(-c2cccc(C(F)(F)F)c2)n2nc(Nc3ccc(OCCN4CCCC4)cc3)ncc12 |
| InChI | InChI=1S/C25H25F3N6O/c1-17-22-16-29-24(31-20-7-9-21(10-8-20)35-14-13-33-11-2-3-12-33)32-34(22)23(30-17)18-5-4-6-19(15-18)25(26,27)28/h4-10,15-16H,2-3,11-14H2,1H3,(H,31,32) |
| InChIKey | XXEFWTLZRFQXAQ-UHFFFAOYSA-N |
| XLogP | 5.34 |
| TPSA | 67.58 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 482.51 |
| LogP ≤ 5 | 5.34 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 11237028 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.